Nursing Home & Elder Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Nursing Home & Elder Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Sunesis Completes Enrollment of Voreloxin REVEAL-1 Trial in Acute Myeloid Leukemia
November 15th, 2009
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules. "The REVEAL-1 trial's rapid accrual from initiation in May 2008 underscores a strong interest from investigators in voreloxin as a potential new treatment for AML," said Daniel Swisher, Chief Executive Officer of Sunesis. "Previously...
Source: Nursing Home & Elder Business Week (2009-11-15)
|
